Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16,998 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma.
Zhang L, Yao Y, Zhang S, Liu Y, Guo H, Ahmed M, Bell T, Zhang H, Han G, Lorence E, Badillo M, Zhou S, Sun Y, Di Francesco ME, Feng N, Haun R, Lan R, Mackintosh SG, Mao X, Song X, Zhang J, Pham LV, Lorenzi PL, Marszalek J, Heffernan T, Draetta G, Jones P, Futreal A, Nomie K, Wang L, Wang M. Zhang L, et al. Among authors: yao y. Sci Transl Med. 2019 May 8;11(491):eaau1167. doi: 10.1126/scitranslmed.aau1167. Sci Transl Med. 2019. PMID: 31068440
Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma.
Wang J, Wang J, Lopez E, Guo H, Zhang H, Liu Y, Chen Z, Huang S, Zhou S, Leeming A, Zhang RJ, Jung D, Shi H, Grundman H, Doakes D, Cui K, Jiang C, Ahmed M, Nomie K, Fang B, Wang M, Yao Y, Zhang L. Wang J, et al. Among authors: yao y. Blood Cancer J. 2019 Nov 28;9(12):95. doi: 10.1038/s41408-019-0259-8. Blood Cancer J. 2019. PMID: 31780660 Free PMC article. No abstract available.
Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.
Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, Han G, Hao D, Hill HA, Jiang C, Yao Y, Nastoupil L, Westin J, Fayad L, Nair R, Steiner R, Ahmed S, Samaniego F, Iyer SP, Oriabure O, Chen W, Song X, Zhang J, Badillo M, Moghrabi O, Aranda J, Tang G, Yin CC, Patel K, Medeiros LJ, Li S, Vega F, Thirumurthi S, Xu G, Neelapu S, Flowers CR, Romaguera J, Fowler N, Wang L, Wang ML, Jain P. Zhao S, et al. Among authors: yao y. Am J Hematol. 2020 Jun;95(6):623-629. doi: 10.1002/ajh.25796. Epub 2020 Apr 17. Am J Hematol. 2020. PMID: 32239765 Free article. Clinical Trial.
Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma.
Jain P, Zhao S, Lee HJ, Hill HA, Ok CY, Kanagal-Shamanna R, Hagemeister FB, Fowler N, Fayad L, Yao Y, Liu Y, Moghrabi OB, Navsaria L, Feng L, Nogueras Gonzalez GM, Xu G, Thirumurthi S, Santos D, Iliescu C, Tang G, Medeiros LJ, Vega F, Avellaneda M, Badillo M, Flowers CR, Wang L, Wang ML. Jain P, et al. Among authors: yao y. J Clin Oncol. 2022 Jan 10;40(2):202-212. doi: 10.1200/JCO.21.01797. Epub 2021 Nov 19. J Clin Oncol. 2022. PMID: 34797699 Free PMC article. Clinical Trial.
Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo.
Zhang X, Zhang R, Ren C, Xu Y, Wu S, Meng C, Pataer A, Song X, Zhang J, Yao Y, He H, Chen H, Ma W, Wang J, Meric-Bernstam F, Champlin RE, Heymach JV, Rooney CM, Swisher SG, Vaporciyan AA, Roth JA, You MJ, Wang M, Fang B. Zhang X, et al. Among authors: yao y. Blood Adv. 2022 Feb 8;6(3):891-901. doi: 10.1182/bloodadvances.2021006156. Blood Adv. 2022. PMID: 34861697 Free PMC article.
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
Wang ML, Jain P, Zhao S, Lee HJ, Nastoupil L, Fayad L, Ok CY, Kanagal-Shamanna R, Hill HA, Yao Y, Hagemeister FB, Westin JR, Fowler N, Samaniego F, Steiner R, Nair R, Iyer SP, Navsaria L, Badillo M; Mantle Cell Research Group; Feng L, Xuelin H, Nogueras Gonzalez GM, Xu G, Wagner-Bartak N, Thirumurthi S, Santos D, Tang G, Lin P, Wang SA, Jorgensen J, Yin CC, Li S, Patel KP, Vega F, Medeiros LJ, Flowers CR, Wang L. Wang ML, et al. Among authors: yao y. Lancet Oncol. 2022 Mar;23(3):406-415. doi: 10.1016/S1470-2045(21)00638-0. Epub 2022 Jan 21. Lancet Oncol. 2022. PMID: 35074072 Clinical Trial.
16,998 results
You have reached the last available page of results. Please see the User Guide for more information.